CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Related Companies

Read the original article

Published by GlobeNewswire Clinical Studies on July 27, 2026 12:17 PM

Read Original